Skip to content
Search AI Powered

Latest Stories

DHSC updates June 2023 price concessions after CPE members report medicine pricing issues

Department of Health and Social Care (DHSC) has updated the final price concessions for June 2023, following a discussion by Community Pharmacy England regarding medicine pricing issues reported by pharmacy owners (its members).

A price concession only applies for the month it is granted; any prices agreed for concessions requested late in the month will roll over into the following month.


Community Pharmacy England encouraged pharmacies to report any problems obtaining a Part VIII product at or below the stated Drug Tariff price, using the online feedback form on the Community Pharmacy England website along with full details of the supplier and price paid for any products sourced above the Drug Tariff price.

The association will investigate the extent of the problem and, if appropriate, discuss the issue with DHSC.

“Since this announcement, we have sent a strong and clear message back to Government that pharmacies cannot continue to subsidise the NHS medicines bill. Following the review of the concessionary price process, a package of measures has been developed to improve the system,” said CPE.

One of the solutions agreed between CPE and DHSC is that from 1st April 2023, all products granted a concessionary price will be classified as ‘Discount Not Deducted’ for the month(s) in which they are on concession.

Furthermore, from May 2023, DHSC has implemented a process to roll over prices to the following month for any concessions requested after the 23rd of the month provided these prices were agreed with us.

CPE is also continuing to work with DHSC on how a ‘retrospective increased payment’ my apply, when appropriate.

Full list below:

DrugPack sizePrice concession
* Alginate raft-forming oral suspension sugar free500£3.80
Amiloride 5mg tablets28£13.46
Amoxicillin 125mg/5ml oral suspension sugar free100£2.68
Benzoyl peroxide 5% / Clindamycin 1% gel60£22.22
Buprenorphine 8mg sublingual tablets sugar free7£11.36
Calamine lotion200£1.86
Chloramphenicol 0.5% eye drops10£12.51
Chlorphenamine 2mg/5ml oral solution sugar free150£4.01
Clotrimazole 500mg pessary and Clotrimazole 2% cream1£10.79
Co-careldopa 12.5mg/50mg tablets90£4.93
Co-trimoxazole 80mg/400mg tablets28£2.34
Docusate 50mg/5ml oral solution sugar free300£18.81
Flucloxacillin 250mg capsules28£2.45
Isoniazid 100mg tablets28£60.00
Ivabradine 5mg tablets56£28.33
Letrozole 2.5mg tablets14£6.66
Methylphenidate 5mg tablets30£3.45
Mometasone 0.1% cream30£3.60
Mycophenolate mofetil 500mg tablets50£7.69
Pantoprazole 20mg gastro-resistant tablets28£6.62
Pantoprazole 40mg gastro-resistant tablets28£9.23
Paracetamol 500mg effervescent tablets100£10.34
Pregabalin 300mg capsules56£4.02
Promethazine hydrochloride 25mg tablets56£29.32
Quinine sulfate 200mg tablets28£7.97
Risperidone 500microgram tablets20£2.98
Rosuvastatin 20mg tablets28£4.98
Sodium chloride 0.9% nebuliser liquid 2.5ml unit dose ampoules20£11.04
Tacrolimus 0.1% ointment60£41.69
Tacrolimus 0.1% ointment30£22.36
Tamsulosin 400microgram / Dutasteride 500microgram capsules30£14.53
Tolterodine 2mg tablets56£3.55
Topiramate 100mg tablets60£16.53
Tramadol 37.5mg / Paracetamol 325mg tablets60£7.38
Trazodone 50mg capsules84£3.45
Venlafaxine 75mg tablets56£11.51
Zolmitriptan 2.5mg tablets6£18.85
Zolmitriptan 2.5mg tablets12£37.70

More For You

New professional liability insurance policy for RPS members launched

The insurance will be provided to members at cost, with no profit made by RPS.

gettyimages

RPS launches professional liability insurance for members

The Royal Pharmaceutical Society (RPS) has launched a new professional liability insurance policy, designed to empower pharmacists to work confidently and deliver high-quality care, knowing they are protected.

Exclusively available to its members, the comprehensive and affordable insurance has been developed in collaboration with global professional services firm Aon.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less